Petros Pharmaceuticals Inc Stock Price, News & Analysis

Petros Pharmaceuticals (Nasdaq: PTPI) announced that President Fady Boctor will present a corporate overview at the LD Micro Virtual Invitational Conference from June 8 to 10, 2021. Boctor's presentation is scheduled for June 10 at 4:00pm ET, Track 1. Investors can register to watch the presentation here. The company focuses on developing innovative therapeutics for men's health issues, including erectile dysfunction and Peyronie's disease.

Petros Pharmaceuticals (PTPI) reported a strong Q1 2021, with net sales reaching $4.1 million, up 300% from Q1 2020. The increase was driven by a 23% rise in STENDRA® prescriptions, achieving an all-time high. Gross margins expanded to 84% from 56% in the previous year. The company posted a net income of $3.0 million, improving from a net loss of $6.1 million. Operating expenses decreased by 22% to $3.9 million. The robust performance reflects effective sales initiatives and a favorable post-COVID environment.

Petros Pharmaceuticals (Nasdaq: PTPI) announced its participation at the Investor Summit Conference on May 18, 2021. President and Chief Commercial Officer Fady Boctor will present at 9:30am ET. Investors can also arrange one-on-one meetings with Mr. Boctor after the conference. The company aims to lead in men's health therapeutics, focusing on issues like erectile dysfunction and Peyronie's disease. Interested investors can register for the conference here.

Petros Pharmaceuticals (Nasdaq: PTPI) will present at the Benzinga Global Small Cap Conference on May 13, 2021. Fady Boctor, President and Chief Commercial Officer, is set to deliver his corporate presentation at 10:50am ET. Investors interested in a one-on-one meeting can request arrangements after the event. Petros Pharmaceuticals aims to lead in specialized men's health by developing innovative therapeutics addressing issues such as erectile dysfunction, Peyronie's disease, and hormone health.

Petros Pharmaceuticals (NASDAQ: PTPI) announced preliminary research on Stendra® (avanafil) for enhancing endothelial function in men with erectile dysfunction (ED), aiming for FDA discussions to expand its labeling. The peer-reviewed study, involving 140 participants, indicated significant improvements in nitric oxide and erectile function with daily avanafil compared to placebo. Stendra, FDA-approved since 2013, has previously been recognized for its rapid onset of action. However, the study had limitations, including a small sample size and short follow-up, necessitating further research.

Petros Pharmaceuticals (NASDAQ: PTPI) announced the appointment of Dr. Mohit Khera to its steering committee to enhance patient access for STENDRA^® (avanafil), a treatment for erectile dysfunction (ED). Dr. Khera, a Urology Professor at Baylor College of Medicine, aims to explore potential over-the-counter availability for STENDRA^® in the U.S., reflecting on successful non-prescription models in other countries. This initiative is part of Petros's strategy to bolster the relaunch of STENDRA^®, which generated approximately $30 million in revenue in 2019.

Petros Pharmaceuticals (Nasdaq: PTPI) announced the formation of a steering committee aimed at expanding access to its erectile dysfunction medication, Stendra® (avanafil), potentially moving towards Over the Counter (OTC) status. This initiative builds upon two years of efforts to enhance patient engagement. Key committee members include industry veterans experienced in Rx to OTC transitions. Stendra® generated approximately $30 million in gross revenues in 2019 and is covered for 75% of commercially insured lives. The company aims to accelerate Stendra®'s relaunch with a focused strategy.

Petros Pharmaceuticals (Nasdaq: PTPI) announces that its president and chief commercial officer, Fady Boctor, will present at NobleCon17 on January 20, 2021, at 9:00 AM ET. The presentation will be part of a virtual investor conference, free to attend for interested investors.

A video webcast will be available the following day on the company's website and on Channelchek, which will also rebroadcast the presentation next month. Petros focuses on innovative therapeutics addressing men's health issues, including erectile dysfunction and Peyronie's disease.

Synaptogenix, Inc. (OTC: SNPX) successfully spun off from Neurotrope Bioscience, focusing on neuro-restorative therapies for Alzheimer's and other neurodegenerative diseases. The lead compound, Bryostatin-1, has shown safety and cognitive improvement in clinical studies. Synaptogenix is advancing its NIH Phase 2 trial, extending dosing to six months, and exploring additional NIH grants. Management emphasizes strategic realignment to enhance shareholder value. The company is poised for growth amid rising interest in new treatment strategies for cognitive diseases.